Longer-acting treatments for neovascular age-related macular degeneration—present and future
Sign Up to like & getrecommendations! Published in 2021 at "Eye"
DOI: 10.1038/s41433-020-01309-9
Abstract: The treatment of neovascular AMD (nAMD) has been revolutionized by the introduction of anti-vascular endothelial growth factor (VEGF) agents. Though, there is a tremendous gap between the outcomes in randomized clinical trials and real-world settings,… read more here.
Keywords: treatments neovascular; acting treatments; present future; neovascular age ... See more keywords
Changes of HbA1c variability after the switch to a longer‐acting insulin analog in people with type 1 diabetes
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13941
Abstract: This study investigated whether longer‐acting basal analogs (insulin degludec and insulin glargine U300) could reduce visit‐to‐visit hemoglobin A1c (HbA1c) variability in patients with type 1 diabetes. Ninety adults with type 1 diabetes for whom the… read more here.
Keywords: switch; hba1c variability; type diabetes; longer acting ... See more keywords